TY - JOUR
T1 - Current and evolving therapies for metastatic pancreatic cancer
T2 - Are we stuck with cytotoxic chemotherapy?
AU - Varadhachary, Gauri R.
AU - Wolff, Robert A.
N1 - Publisher Copyright:
Copyright © 2016 by American Society of Clinical Oncology.
PY - 2016/9
Y1 - 2016/9
N2 - At present, front-line therapy for metastatic pancreatic ductal adenocarcinoma is combination chemotherapy, most commonly FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) or gemcitabine and nanoparticle albumin-bound paclitaxel. Despite a better understanding of the genomic landscape and the importance of the tumor microenvironment, we have not made a seismic shift in the overall survival for this disease. Given our growing understanding of the biology of pancreatic ductal adenocarcinoma, the question remains whether novel, noncytotoxic agents will augment or even replace conventional chemotherapy. The thrust of ongoing efforts can be divided into broad categories, including exploiting the DNA damage repair phenotype, stroma and specific pathway-targeting agents, and enhancing immune destruction of pancreatic ductal adenocarcinoma. In this article, we review the current and evolving therapeutic landscape of metastatic pancreatic cancer.
AB - At present, front-line therapy for metastatic pancreatic ductal adenocarcinoma is combination chemotherapy, most commonly FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) or gemcitabine and nanoparticle albumin-bound paclitaxel. Despite a better understanding of the genomic landscape and the importance of the tumor microenvironment, we have not made a seismic shift in the overall survival for this disease. Given our growing understanding of the biology of pancreatic ductal adenocarcinoma, the question remains whether novel, noncytotoxic agents will augment or even replace conventional chemotherapy. The thrust of ongoing efforts can be divided into broad categories, including exploiting the DNA damage repair phenotype, stroma and specific pathway-targeting agents, and enhancing immune destruction of pancreatic ductal adenocarcinoma. In this article, we review the current and evolving therapeutic landscape of metastatic pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84987657582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987657582&partnerID=8YFLogxK
U2 - 10.1200/JOP.2016.015586
DO - 10.1200/JOP.2016.015586
M3 - Review article
C2 - 27621332
AN - SCOPUS:84987657582
SN - 1554-7477
VL - 12
SP - 797
EP - 805
JO - Journal of oncology practice
JF - Journal of oncology practice
IS - 9
ER -